| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Envoy Medical, Inc.$0.68
-0.01 (-1.62%)
F 2Pipeline Score MedTech · Clinical
Market Cap
54.51 M
EPS
-1.03
P/E Ratio
-
Value Trade
32.48 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
39.00 K
R&D Expenses
3.64 M
Operating CF
-6.06 M
Total Assets
29.82 M
Total Liabilities
19.27 M
Equity
10.16 M
D/E Ratio
12,345
9.06 %
Week
-0.14 %
1 Month
-5.47 %
3 Month
1.72 %
6 Month
-92.72 %
5 Year
-92.74 %
All Time
Cash Data
Cash Position
25.25 M
Monthly Burn
2.02 M
Runway
10.7 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
73.62 K
52 Week Range
0.36 - 1.89
% held by Insiders
40.5 %
% held by Institutions
22.83 %
Enterprise Value
30.15 M
Total Shares
76.92 M
Short %
2.36 %
Float Shares
41.77 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 866 of 911)
Percentile RankEnvoy Medical, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COCH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COCH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
COCH▲ +16%on this news
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
Envoy Medical has submitted the first module of its Modular Premarket Approval application to the FDA for its Breakthrough Device-designated cochlear implant. This modular approach allows for earlier FDA engagement and iterative feedback, reducing regulatory risks. The company plans to submit a total of four modules, with the final one expected in Q2 2027, providing investors with visibility into progress.
Read more →COCH▲ +6.7%on this news· ran to +26% by day 3shared move
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
Envoy Medical has terminated its at-the-market equity facility, reflecting its confidence in its current capital position. The company, known for its innovative hearing solutions, had previously authorized the sale of up to $15 million in shares. This decision is seen as a positive step towards strengthening its financial standing as it continues to develop unique hearing devices.
Read more →COCHEnvoy Medical to Present at Investor Conferences on June 25th
Envoy Medical Inc. (NASDAQ: COCH) will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. CEO Brent Lucas will discuss the company's innovative fully implanted hearing solutions, including the Esteem and Acclaim cochlear implants. The Acclaim CI is designed for severe to profound sensorineural hearing loss and has received FDA Breakthrough Device Designation.
Read more →COCHEnvoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
Envoy Medical Inc. (NASDAQ: COCH) will present at the Planet MicroCap Conference in Las Vegas from June 16-18, 2026. CEO Brent Lucas will speak on June 17 at 11:00 A.M. PT. The company will also hold one-on-one investor meetings during the event. Envoy Medical focuses on innovative hearing solutions, including the Esteem and Acclaim cochlear implants.
Read more →COCHEnvoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-Of-Its-Kind Fully Implanted Cochlear Implant Company Completes Historic Trial Enrollment, Secures Transformational Financing, and See
Envoy Medical has announced significant progress in advancing its investigational Acclaim cochlear implant towards FDA approval. The company successfully completed enrollment in its pivotal clinical trial, an important milestone for achieving market entry. Additionally, Envoy has raised up to $78 million in financing, further strengthening its resources for commercialization. Promising initial clinical data indicates improvements in patient outcomes, bolstering confidence in the product's potential.
Read more →COCHEnvoy Medical Reports Full Year 2025 Financial Results Received FDA approval to expand fully implanted Acclaim Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 millio
Envoy Medical reported its financial results for 2025, highlighting significant achievements including FDA approval to expand its pivotal clinical trial for the Acclaim cochlear implant. The company successfully raised capital and strengthened its balance sheet by eliminating $32 million in debt. This progress sets a positive outlook for 2026, as Envoy continues to gather data and prepare for a PMA submission to the FDA. Additionally, Envoy aims to enhance global patent protection for its hearing technology innovations.
Read more →COCH▲ +6.7%on this news
Envoy Medical Regains Compliance with Nasdaq Listing Requirement White Bear Lake, Minnesota
Envoy Medical Inc. has officially regained compliance with Nasdaq listing requirements, following a notice of non-compliance issued in February 2025. The company implemented effective strategic financing initiatives that significantly strengthened its balance sheet. Following these changes, Envoy Medical is now positioned to maintain its listing on the Nasdaq Capital Market under the symbol 'COCH'. The company is focused on providing innovative hearing health solutions, including their fully implanted devices for hearing loss.
Read more →COCH▼ -20.5%on this news
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering $30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-lin
Envoy Medical Inc. announced the successful closing of a $78 million upsized public offering, securing $30 million upfront and up to $48 million from milestone-linked warrants. This financing aims to extend the company's cash runway into 2027, well beyond their expected PMA submission timeline. The offering was anchored by Nantahala Capital and saw participation from existing shareholder Glen Taylor and several healthcare funds. The funds raised will primarily support the company's operations and pivotal clinical studies for their Acclaim cochlear implant, which is currently in development.
Read more →COCH▲ +69.2%on this newsshared move
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering
Envoy Medical has announced the pricing of an upsized public offering aimed at raising up to $78.0 million. This move reflects the company's strategy to enhance its financial position and support future growth. The offering is expected to attract significant investor interest, highlighting confidence in the company's prospects.
Read more →COCHEnvoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5
Envoy Medical Inc. announced its participation in the Small Cap Growth Virtual Investor Conference scheduled for February 5, 2026. During the event, company management will discuss their innovative hearing solutions and answer investor queries in real time. Attendees unable to join live can access a recording afterward. Envoy Medical is known for its pioneering work in fully implanted hearing devices, including the Esteem active middle ear implant and the investigational Acclaim cochlear implant.
Read more →COCHINVESTOR PRESENTATION DECEMBER 2025 www.envoymedical.com NASDAQ: COCH Hear for Life Nasdaq: COCH 2 FORWARD LOOKING STATEMENTS This presentation includes "forward - looking statements" within the meaning of the "safe harb
Envoy Medical presented its investment highlights, focusing on the Acclaim CI, the first fully implanted cochlear implant aimed at transforming the hearing health market. The company is currently in the late stages of development, with pivotal trials expected to be completed by Q1 2026. The presentation emphasized the potential market size of $84 billion in the U.S. for cochlear implants and highlighted the distinct features of the Acclaim CI, which are designed to improve the user experience significantly.
Read more →COCHEnvoy Medical Announces the Grant of Its 40th U.S. Patent
Envoy Medical has announced the grant of its 40th active U.S. patent, enhancing its intellectual property portfolio which includes 45 foreign patents. The new patent covers technology for cochlear implant systems that improve performance and reliability. The Acclaim cochlear implant, which received Breakthrough Device Designation from the FDA, is currently being tested in a pivotal clinical trial.
Read more →COCHEnvoy Medical Reports Third Quarter 2025 Financial and Operational Results Transformational quarter puts Envoy Medical in significantly better position as it eliminated $32 million of debt, strengthened its balance sheet
Envoy Medical reported a transformative third quarter for 2025, significantly improving its position by eliminating $32 million in debt and receiving FDA approval to expand its pivotal clinical trial. The company successfully enrolled the first three patients in this final stage and expanded its patent portfolio with several new global patents. Additionally, they announced a direct offering aimed at raising up to $16 million. These advancements position Envoy Medical favorably in the hearing health market amidst their ongoing clinical efforts.
Read more →COCHEnvoy Medical Receives Positive Listing Determination from Nasdaq White Bear Lake, MN
Envoy Medical, Inc. (NASDAQ: COCH) announced that it has received a positive listing determination from the Nasdaq Hearings Panel, allowing for continued listing on the stock market. This decision is underpinned by notable factors such as improved stockholders' equity following recent capital raises and the progression of the Acclaim cochlear implant into its final clinical trial phase. The company now has until February 23, 2026, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2). Envoy Medical has highlighted an increase in investor interest, with trading volumes rising post-trial announcement.
Read more →COCHEnvoy Medical to Present at the Virtual Technology Investor Conference on October 28th
Envoy Medical, a company specializing in innovative fully implanted hearing solutions, is set to present at the Virtual Technology Investor Conference on October 28, 2025. CEO Brent Lucas will lead the presentation, which aims to update investors on the company's progress and developments. Recently, Envoy Medical received FDA approval to move its pivotal clinical trial to the final stage and has secured multiple global patents for its cochlear implant technology. Additionally, the company closed a $16 million direct offering, demonstrating strong investor support.
Read more →COCH▼ -41.5%on this news
Envoy Medical Announces Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $4 million upfront with up to additional $12 million of potential aggregate gross proceeds upon the exercise in
Envoy Medical, a hearing health company, announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise up to $16 million. The plan includes selling approximately 3 million shares at $1.33 each, alongside unregistered warrants that could generate an additional $12 million if exercised. The proceeds will support working capital and general corporate needs. The offering is expected to close by October 9, 2025, subject to standard closing conditions.
Read more →COCH▲ +97.1%on this newsshared move
Envoy Medical Receives FDA Approval to Advance its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data The Company expects to complete full enrollment by early 2026 and is moving its t
Envoy Medical has received FDA approval to advance its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage. The approval, based on promising three-month data from the first 10 patients, enables the company to shorten its timeline to commercialization by three to six months while also reducing anticipated capital needs by $10-$15 million. The trial will expand to include an additional 46 participants across seven sites, with indications of high interest in the investigational device. This advancement positions Envoy Medical to redefine industry standards in cochlear implants.
Read more →COCH▼ -27.9%on this news
Envoy Medical Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules White Bear Lake, Minnesota
Envoy Medical Inc. announced a registered direct offering of 1,908,402 shares of its Class A common stock for $1.31 per share, generating estimated proceeds of $2.5 million. Additionally, the company is issuing unregistered warrants that could provide up to $7.5 million more upon exercise. The offering is set to close around September 23, 2025, pending customary conditions. Funds from the offering will be used for working capital and corporate purposes, although there are risks associated with the warrants potentially expiring unexercised.
Read more →COCHEnvoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology Patent covers advanced signal processing for middle ear sensors, further advancing the Company's
Envoy Medical Inc. has secured a new European patent for its cochlear implant technology, specifically covering advanced signal processing for middle ear sensors. This patent strengthens the company's global portfolio, following prior issuances in regions such as the United States and Australia. The technology, designed for fully implanted hearing solutions, aims to enhance patient outcomes for those experiencing severe to profound sensorineural hearing loss. Envoy Medical's CEO asserts that the patent reflects the company’s commitment to innovation in hearing technology.
Read more →COCHEnvoy Medical Extinguishes Over $32 Million in Debt, Strengthening Balance Sheet Announces Retirement of Glen A. Taylor from Board Extinguishment simplifies capital structure, strengthens foundation for growth, and elimi
Envoy Medical has paid off over $32 million in debt to GAT Funding, simplifying its capital structure and strengthening its growth foundation. The repayment was facilitated by a payment of just $100,000, which significantly improves the company's financial health. Glen A. Taylor, the owner of GAT Funding, has retired from the company's board after nearly two decades, expressing confidence in Envoy Medical's future. With a strong balance sheet, the company aims to focus on advancing its lead product, the investigational Acclaim cochlear implant.
Read more →COCH▼ -6.2%on this news
Envoy Medical Reports on Second Quarter 2025 Results White Bear Lake, Minnesota - (
Envoy Medical, Inc. reported its financial results for the second quarter ending June 30, 2025, showing an increase in net revenues and significant advancements in clinical studies. The Acclaim trial achieved successful activation of all participants, with no reported serious adverse events. The company expressed optimism for future market penetration with the Acclaim cochlear implant, as well as potential for growth in the Esteem middle ear implant amid anticipated changes in reimbursement. However, increases in general and administrative expenses raised concerns regarding financial management.
Read more →COCHEnvoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Envoy Medical, a hearing health company focused on implanted hearing devices, announced that its CEO Brent Lucas will present at the Life Sciences Virtual Investor Forum on June 12, 2025. This live online event allows for real-time interaction with investors, who can ask questions and access archived content afterward. The company recently highlighted its positive clinical trial progress for its Acclaim Cochlear Implant, indicating strong momentum in its innovative product development. Envoy continues to push the boundaries of hearing technology with its commitment to improving accessibility and quality of life.
Read more →COCHEnvoy Medical Reports on First Quarter 2025 Results Company Provides Update on its Pivotal Clinical Study for Fully Implanted Cochlear Implant WHITE BEAR LAKE, Minnesota--(Newsfile Corp.
Envoy Medical, Inc. has reported its financial results and provided an update on its pivotal clinical study for the fully implanted Acclaim Cochlear Implant. The company experienced a decrease in net revenues primarily due to supply chain issues, but noted positive momentum in clinical study enrollment. CEO Brent Lucas expressed excitement over the initial patient feedback, highlighting a strong interest in the innovative features of the device. Despite some financial setbacks, the company aims to advance its fully implanted cochlear implant technology in the hearing health industry.
Read more →COCHEnvoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Devi
Envoy Medical reported its financial results for the fourth quarter and full year 2024, highlighting achievements in its clinical progress. The company obtained FDA approval to start a pivotal clinical trial for its Acclaim Cochlear Implant and noted strong enrollment and patient interest. However, net revenues decreased due to supply chain limitations affecting battery replacement sales. Additionally, the company faces increased R&D and marketing expenses as it prepares for the trial and seeks to secure reimbursement for its devices.
Read more →COCH▲ +8.9%on this news
Envoy Medical Secures $10 Million in Funding to Advance Pivotal Clinical Trial of Breakthrough Hearing Device Billionaire Entrepreneur Glen Taylor, the Company's Largest Shareholder, Continues to Invest Significant Capit
Envoy Medical has successfully secured $10 million in funding from its largest shareholder, Glen Taylor, to support its pivotal clinical trial for the fully implanted Acclaim cochlear implant. The financing comes at a critical time as the company anticipates important milestones in what it considers a transformative year. CEO Brent Lucas highlighted the growing interest from investigational sites in the Acclaim CI, indicating a positive outlook for future enrollment and market acceptance.
Read more →COCHEnvoy Technologies, a Blink Charging Subsidiary, Files Registration Statement for Proposed Initial Public Offering of Shares
Blink Charging Co. has filed a registration statement for the initial public offering of its subsidiary, Envoy Technologies, which specializes in electric vehicle car-sharing services. The proposed offering, which aims to list under the ticker symbol 'EVOY' on The Nasdaq Capital Market, does not yet have specific details on the number of shares or pricing. The filing is subject to regulatory review and other market conditions. Envoy's services are designed to enhance urban mobility and support sustainable transportation initiatives.
Read more →COCH▼ -10.2%on this news
Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss
Envoy Medical has announced the issuance of four new patents related to its innovative cochlear implant technologies, further strengthening its intellectual property portfolio. The patents focus on enhancing the functionality of cochlear implants in conjunction with hearing aids and improving calibration methods. CEO Brent Lucas emphasized the company's dedication to ongoing innovation in the hearing loss space. The Acclaim Cochlear Implant, a fully implanted device designed for severe to profound sensorineural hearing loss, is highlighted as a promising solution for patients.
Read more →COCH▲ +8.7%on this news
Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved full
Envoy Medical announced its financial results for the third quarter of 2024 along with significant milestones for its products. The company received FDA approval to initiate a pivotal trial for its Acclaim fully implanted cochlear implant and obtained AMA approval for new CPT codes related to middle ear implants. Despite these positive developments, Envoy reported a decrease in net revenues primarily due to fewer battery replacement requests and ongoing supply chain challenges. The company emphasized its commitment to advancing reimbursement strategies for its innovative hearing devices.
Read more →COCHEnvoy Medical’s Fully Implanted Acclaim Cochlear Implant Highlighted in Peer-Reviewed Publication
Envoy Medical announced a peer-reviewed publication discussing early experiences with its Acclaim Cochlear Implant. The paper, featured in Otology & Neurotology, highlights potential benefits observed in a first-in-human feasibility study involving three patients. Positive outcomes include improved speech and quality of life noted by the patients, as well as the device's capability to be used continuously and at night. The company is preparing to expand this study following FDA approval for a pivotal clinical trial.
Read more →COCHEnvoy Medical Receives Another European Patent for its Modular Cochlear Implant System
Envoy Medical, a hearing health company, has been granted a European patent for its Implantable Modular Cochlear Implant System. This new technology aims to enhance hearing for individuals with severe to profound sensorineural hearing loss. The fully implanted Acclaim Cochlear Implant leverages the ear's natural anatomy rather than a microphone to capture sound. With the FDA's Breakthrough Device Designation in 2019, this product marks a significant advancement in hearing devices.
Read more →COCHEnvoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
Envoy Medical has received FDA approval to initiate a pivotal clinical study for its Acclaim Fully Implanted Cochlear Implant, which aims to provide a new option for patients with severe to profound hearing loss. The technology is distinguished by an implanted sensor designed to utilize the ear's natural anatomy. Interest from leading cochlear implant institutions in participating in the study reflects potential market demand. The approval underscores Envoy Medical's commitment to innovation in the hearing industry, though results from the study remain uncertain until data is collected.
Read more →COCH▼ -5.9%on this news
Envoy Medical to Present at the LD Micro Main Event XVII
Envoy Medical, a company specializing in fully implanted hearing systems, announced that CFO David R. Wells will present at the LD Micro Main Event XVII on October 29, 2024. The conference will take place at the Luxe Sunset Boulevard Hotel in Los Angeles. The Esteem fully implanted active middle ear implant, designed for adults with moderate to severe sensorineural hearing loss, is highlighted as a key product in their portfolio. Mr. Wells will also be available for one-on-one meetings with registered investors during the event.
Read more →COCHEnvoy Technologies Inc. Launches Turnkey, On-Demand Luxury Lucid EV Sharing as an Amenity
Envoy Technologies Inc. has launched a luxury car-sharing service featuring Lucid Air EVs at three properties in California. This initiative allows residents to access these high-end vehicles through an app and charge them at no extra cost. The program is designed to enhance living standards and is part of Envoy’s goals to expand its services across the United States. The company aims to collaborate with more property owners to provide their innovative EV-sharing solutions.
Read more →COCH▼ -17.8%on this newsshared move
Envoy Medical Celebrates First Anniversary Trading as a Public Company under COCH on Nasdaq Capital Market
Envoy Medical is celebrating its first anniversary trading on the Nasdaq Capital Market under the ticker COCH. The company has made notable strides in the hearing implant sector, positioning itself to take market share from competitors. CEO Brent Lucas highlighted the company's performance post-deSPAC, indicating it is among the top performers in its peer group. Furthermore, Envoy Medical is advancing plans for its fully implanted devices amid potential legislative changes that may affect Medicare coverage, which presents both opportunities and uncertainties for the company.
Read more →COCHEnvoy Medical Awarded Patent for Recharge System used with Implantable Battery
Envoy Medical, Inc. has been awarded a new patent for its 'Recharge System for Implantable Battery,' enhancing the safety of its fully implanted hearing devices. The patent focuses on managing the thermal dose during the recharging process to maintain safe temperatures. This addition to their patent portfolio supports the company's mission to develop innovative solutions for individuals with significant hearing loss. Envoy Medical’s CEO highlighted the importance of this technology in mitigating risks associated with implanted medical devices.
Read more →COCHEnvoy Medical Secures Lending Facility of $10M
Envoy Medical has entered into a $10 million lending facility primarily funded by investor Glen Taylor. The company plans to use the funds to maintain momentum while pursuing critical milestones, including an Investigational Device Exemption for their fully implanted Acclaim cochlear implant. The facility is unsecured with a two-year interest deferment and an 8% interest rate over five years. This funding aims to support advancements in hearing devices and potentially improve access for those with severe to profound hearing loss.
Read more →COCHEnvoy Medical Secures Lending Facility of $10M Glen Taylor, Committed Investor and Believer in Envoy Medical's Mission to Help People with Significant Hearing Loss, Provides Significant Additional Funding as the Company
Envoy Medical announced the securing of a $10 million lending facility from Glen Taylor, which will provide crucial funds to advance its development of innovative hearing devices. The company aims to launch the fully implanted Acclaim cochlear implant, anticipated to transform the industry for individuals with severe hearing loss. CEO Brent Lucas expressed confidence that this funding will help maintain momentum and advance their mission. Additionally, Envoy has plans to seek Investigational Device Exemption to begin pivotal studies shortly.
Read more →COCH▲ +19.5%on this news
Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrou
Envoy Medical, a leader in hearing health technology, reported its financial results for Q2 2024, showcasing steady progress in its development of the fully implanted Acclaim Cochlear Implant. The company aims to commence a Pivotal Clinical Trial by year-end, pending IDE application approval. Despite revenue growth from implant sales, Envoy faced increased operating expenses and supply chain challenges that impacted overall financial performance. The Acclaim CI is expected to address profound sensorineural hearing loss effectively.
Read more →COCH▲ +14.4%on this news
Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthetics, Not Hearing Aids, Making Them Eligible for Medicare Coverage Envoy Medical's FDA-Approved Esteem Fully Implanted A
Envoy Medical supports the bipartisan Hearing Device Coverage Clarification Act, which aims to define implanted active middle ear hearing devices as prosthetics eligible for Medicare coverage. The bill, introduced in the Senate, seeks to improve access to advanced hearing solutions for patients with significant hearing loss. Envoy Medical believes this legislation will drive competition, innovation, and job creation in the sector. The company emphasizes the importance of such technology for nearly 40 million Americans suffering from disabling hearing loss.
Read more →COCHEnvoy Technologies Inc to Provide Turnkey, On-Demand Rivian EVs and Blink Charging Stations as an Amenity to Indigo Neighborhood in Fort Bend County, Texas
Envoy Technologies Inc. has partnered with Meristem Communities to provide electric vehicle car-sharing services at the Indigo neighborhood in Fort Bend County, Texas. This initiative allows residents to access Rivian R1T vehicles via a mobile app and make use of on-site charging stations at no extra cost. The Indigo development aims to create a community-centered living environment with a focus on sustainability and convenience. As part of the introduction, residents will receive complimentary rental time upon moving in and the option to book vehicles up to a year in advance.
Read more →COCHINVESTOR PRESENTATION July 2024 www.envoymedical.com NASDAQ: COCH Hear for Life Nasdaq: COCH 2 FORWARD LOOKING STATEMENTS This presentation includes "forward - looking statements" within the meaning of the "safe harbor"
Envoy Medical, trading as COCH on NASDAQ, recently held an investor presentation outlining its business goals and forward-looking statements regarding its innovative hearing implant technologies. The company is the only one with an FDA-approved fully implanted hearing device. With financial metrics indicating a strong cash balance and market capitalization, Envoy aims to improve access to hearing healthcare. However, challenges regarding regulatory approvals and competition in the medical device industry were also highlighted as potential risks.
Read more →COCHEnvoy Medical Announces Inclusion in the Russell Microcap Index
Envoy Medical, a hearing health company trading under the ticker COCH, has been included in the Russell Microcap Index as of June 28, 2024. The company's leadership believes this inclusion will boost visibility and attract more investors to their innovative fully implanted hearing technologies. Notably, Envoy Medical's Acclaim Cochlear Implant aims to address severe hearing loss using a unique sensor technology. The announcement is seen as a significant step in the company's growth trajectory in the medical device market.
Read more →COCH▼ -5.3%on this news
Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling
Envoy Medical has appointed Michael Crowe to its Board of Directors, effective June 7, 2024. Crowe brings extensive experience in medical device manufacturing and operations, which is expected to aid Envoy's growth strategy. The company is currently conducting an Early Feasibility Study for its investigational Acclaim Cochlear Implant at Mayo Clinic, with plans to initiate a larger clinical study later this year. This implant is designed for adults with severe to profound sensorineural hearing loss and has received FDA's Breakthrough Device Designation.
Read more →COCHEnvoy Medical Announces Inclusion in the MSCI USA Micro Cap Index
Envoy Medical, a hearing health company specializing in fully implanted hearing systems, has been included in the MSCI USA Micro Cap Index, effective May 31, 2024. This inclusion is expected to increase the company's visibility and may influence ETF holdings. Envoy's focus on innovative hearing solutions is exemplified by its Acclaim Cochlear Implant, which leverages natural ear anatomy. The Acclaim CI has received Breakthrough Device Designation from the FDA, highlighting its potential impact in treating severe to profound hearing loss.
Read more →COCHEnvoy Medical Reports First Quarter 2024 Results The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry wit
Envoy Medical, a leader in fully implanted hearing devices, announced its financial results for the first quarter of 2024, revealing a decrease in revenue compared to the previous year. Despite a drop in sales, the company remains optimistic about its future, particularly with the Acclaim Cochlear Implant, which aims to disrupt the cochlear implant market and has received FDA Breakthrough Device Designation. The increased R&D expenditures reflect preparations for its pivotal clinical study, although the company faces pressures from rising operational costs.
Read more →COCHEnvoy Medical Reports First Quarter 2024 Results
Envoy Medical, a leader in fully implanted hearing devices, reported its Q1 2024 results, showing both progress and challenges. The company is advancing towards pivotal clinical trials for its Acclaim cochlear implant, with increasing interest from the hearing health community. However, its revenue has declined compared to the previous year, partly due to fewer battery replacement requests. Despite rising expenses in research and general administration, the company secured a $10 million financing agreement that strengthens its financial position.
Read more →COCHEnvoy Medical to Present at the Planet MicroCap Showcase: Vegas 2024
Envoy Medical, Inc. (Nasdaq: COCH), known for its innovative hearing systems, will showcase at the Planet MicroCap Showcase in Las Vegas from April 30 to May 2, 2024. CFO David R. Wells is set to give a corporate overview presentation on May 1, 2024. The Acclaim Cochlear Implant, which utilizes a unique fully implanted technology, is positioned to offer solutions for severe hearing loss and has previously received FDA Breakthrough Device Designation.
Read more →COCH▲ +22.3%on this news· ran to +43% by day 3
Envoy Medical to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Envoy Medical, focused on innovative hearing health solutions, will participate in the LD Micro Invitational XIV Conference on April 8-9, 2024. CEO Brent Lucas and CFO David R. Wells will present a corporate overview and hold one-on-one meetings with investors. The highlight includes discussion of the fully implanted Acclaim Cochlear Implant, which has received Breakthrough Device Designation from the FDA, aiming to address severe to profound hearing loss.
Read more →COCHEnvoy Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Envoy Medical, Inc. announced its fourth quarter and full year 2023 financial results, reporting completion of a business combination and successful trading under its new Nasdaq ticker COCH. The company's investigational Acclaim CI cochlear implant is meeting early feasibility study milestones, with all three patients surpassing the twelve-month post-activation visits. Additionally, Envoy Medical secured significant funding and introduced a bipartisan bill aiming to improve insurance coverage for their Esteem FI-AMEI device. However, the company experienced substantial increases in research and development and general administrative expenses, reflecting the costs associated with its growth and public listing.
Read more →COCHEnvoy Medical to Participate in the 36th Annual ROTH Conference
Envoy Medical, a company specializing in hearing health, will participate in the 36th Annual ROTH Conference from March 17 to 19, 2024. The CFO, David R. Wells, will engage in one-on-one meetings with investors and analysts to provide updates on the company's clinical trials and developments. The company's Acclaim Cochlear Implant is noted for being a potentially groundbreaking product in hearing technology, having previously received Breakthrough Device Designation from the FDA. In addition, Envoy Medical's Esteem FI-AMEI remains a unique offering in the market for severe to profound hearing loss.
Read more →COCH▲ +39.2%on this news
Envoy Medical Secures Up To $10 Million Term Debt Financing to Advance Upcoming Clinical Trial Billionaire Entrepreneur Glen Taylor Commits to a 5-Year Facility to Support Company's upcoming FDA Clinical Trial for the Ac
Envoy Medical has secured up to $10 million in term debt financing from billionaire Glen Taylor to advance its upcoming FDA clinical trial for the Acclaim Fully Implanted Cochlear Implant. The five-year lending facility, which is unsecured and carries an interest rate of 8%, will support the launch of a pivotal clinical trial. The Acclaim cochlear implant has received Breakthrough Device Designation from the FDA, further enhancing its market potential. The funding demonstrates significant investor confidence in Envoy Medical's innovative approach to hearing health.
Read more →COCH▲ +26.8%on this news
Envoy Medical CEO Brent Lucas Interviewed by Leading Healthcare Podcast Medical Alley
Brent Lucas, CEO of Envoy Medical, was featured on the Medical Alley Podcast where he discussed the hearing health market and the need for greater awareness regarding hearing loss treatments. He highlighted the significant opportunity for innovation in the sector, especially with their fully implanted Acclaim Cochlear Implant. This device aims to address severe hearing loss and represents a new frontier in hearing technology. The discussion emphasized the importance of investment in hearing health and the company's commitment to transforming the market.
Read more →COCHEnvoy Medical Announces Three Additional Patents for Implantable Cochlear Systems
Envoy Medical announced the issuance of three new patents related to its implantable cochlear systems, highlighting its commitment to innovation in hearing health. These patents include advanced functionalities such as integrated signal analysis and electrode impedance diagnostics. The CEO expressed optimism for 2024, expecting significant milestones including advancement in clinical trials for the Acclaim Cochlear Implant. This device is designed to enhance hearing for patients with severe to profound sensorineural hearing loss.
Read more →COCH▼ -20.3%on this news
Envoy Medical to Host Fireside Chat Event December 7
Envoy Medical, Inc. will host a fireside chat event on December 7, 2023, where CEO Brent T. Lucas and CFO David R. Wells will discuss the company's innovative products. The event will also involve discussions with Dr. Colin Driscoll and Dr. Aniket Saoji from Mayo Clinic regarding their experiences with the investigational Acclaim cochlear implant. The company's third-quarter results reflect significant progress, and they expect to initiate their clinical program for FDA approval of the Acclaim in 2024.
Read more →COCH▲ +9.9%on this news· ran to +35% by day 3
Envoy Medical Provides Third Quarter 2023 Financial Results and Business Update
Envoy Medical, Inc. announced its third quarter 2023 financial results, highlighting transformative milestones including its merger for Nasdaq listing and progress in the Acclaim® cochlear implant trial. The company is focusing on its pivotal clinical trial planned for 2024, supported by promising early data from the Acclaim® feasibility study which noted improvements in quality of life for participants. Challenges remain, such as addressing a signal to noise issue in the device's design. Envoy Medical aims to educate on the advantages of fully implanted hearing solutions to capture a significant market opportunity.
Read more →COCHEnvoy Medical Announces Publication of Additional Patent for Implantable Cochlear Systems
Envoy Medical has announced the publication of an additional patent for its implantable cochlear systems, aimed at enhancing its product portfolio in the under-penetrated hearing implant market. The new patent, titled 'Implantable Cochlear System with Inner Ear Sensor,' will support the company's strategy to innovate within the hearing health sector. The Acclaim Cochlear Implant, which is expected to provide a breakthrough in treatment for those with severe to profound hearing loss, leverages unique technology designed to improve usability and access. The company remains focused on disrupting the current hearing implant landscape with ongoing technological advancements.
Read more →COCHEnvoy Medical to Present at the Emerging Growth Virtual Conference November 1
Envoy Medical, Inc. (NASDAQ: COCH), a hearing health company, will present at the Emerging Growth virtual investor conference on November 1-2, 2023. The presentation will feature a group discussion and an opportunity for audience questions. Envoy Medical is known for its innovative Acclaim Cochlear Implant, designed for those with severe to profound hearing loss and has previously received Breakthrough Device Designation from the FDA. The company is headquartered in White Bear Lake, Minnesota.
Read more →COCH▼ -27.4%on this news· ran to -40% by day 1
Envoy Medical Announces Settlement Contract
Envoy Medical, Inc. (NASDAQ: COCH) has reached a settlement regarding a lawsuit initiated by certain former shareholders of Envoy Medical Corporation. The lawsuit contested financing transactions involving board member Glen Taylor. Following the settlement, details remain confidential, but the plaintiffs sold their EMC stock to Taylor's affiliate. Envoy Medical aims to innovate the hearing health sector with its Acclaim Cochlear Implant, which received Breakthrough Device Designation from the FDA in 2019.
Read more →COCH▼ -27.4%on this news· ran to -40% by day 1
Envoy Medical Announces Settlement Contract Outstanding Shareholder Claims Resolved
Envoy Medical, Inc. (NASDAQ: COCH) announced a settlement regarding an outstanding lawsuit from former shareholders of its subsidiary, Envoy Medical Corporation. The lawsuit challenged financial transactions involving board member Glen Taylor, which claimed to be in the company's best interest. The settlement, reached in August 2023, allowed the plaintiffs to sell their EMC stock to Mr. Taylor's affiliate, paving the way for Envoy Medical to focus on its strategic goals and product development, particularly the Acclaim Cochlear Implant.
Read more →COCHENVOY MEDICAL CORPORATION AND ANZU SPECIAL ACQUISITION CORP I COMPLETE BUSINESS COMBINATION NASDAQ to list Envoy Medical, developer of an FDA-designated breakthrough device for hearing loss - a novel fully implanted coch
Envoy Medical Corporation has completed its business combination with Anzu Special Acquisition Corp I, officially becoming a publicly traded company on Nasdaq under the ticker COCH. The company is known for its innovative fully implanted cochlear device designed to address hearing loss. With the aging population increasing the demand for such devices, Envoy anticipates reporting key milestones from its clinical trials. However, risks related to regulatory approvals and market performance remain.
Read more →COCHAnzu Special Acquisition Corp I Stockholders Approve Business Combination with Envoy Medical Corporation Tampa, Florida
Anzu Special Acquisition Corp I has received overwhelming approval from its stockholders for a Business Combination with Envoy Medical Corporation. The merger will result in Envoy becoming a wholly owned subsidiary of Anzu, with the company rebranding as Envoy Medical, Inc. The agreement was approved at a special meeting held on September 27, 2023, and is anticipated to close by September 29, 2023. This transaction positions Envoy to enhance its presence in the hearing health sector with innovative medical technologies.
Read more →COCHENVOY MEDICAL | 1 Investor Presentation Hear for Life September 2023 ENVOY MEDICAL | 2 Forward - Looking Statements This "Presentation" includes "forward - looking statements" within the meaning of the "safe harbor" prov
Envoy Medical's investor presentation outlines its Proposed Business Combination with Anzu Special Acquisition Corp I, highlighting forward-looking statements regarding future operational expectations and market performance. The presentation stresses risks associated with the merger, including uncertainties related to stockholder approval and the challenges of retaining key personnel. Additionally, it discusses potential impacts on share price and compliance with regulations in the medical device market. The company acknowledges that actual outcomes may vary significantly due to these factors.
Read more →COCHshall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K") to which this exhibit is attached and, if not defined in the Form 8-K, the definitive proxy statement/prospectus filed with the
The article discusses the unaudited pro forma condensed combined financial statements of Envoy Medical, previously known as Anzu Special Acquisition Corp I, following their business combination. The financial information is provided for illustrative purposes only and outlines various aspects of the combined entity. It also highlights historical financial figures and significant liabilities that could impact future financial performance. As such, investors are cautioned that the provided data may not precisely reflect future operational results.
Read more →COCHENVOY MEDICAL | 1 Investor Presentation Hear for Life ENVOY MEDICAL | 2 This presentation (this "Presentation") is provided for information purposes only and has been prepared to assist interested par ties in making thei
Envoy Medical Corporation is in the process of a Proposed Business Combination with Anzu Special Acquisition Corp I. This investor presentation outlines the terms and conditions of the arrangement, noting that various risks and uncertainties could affect the outcome. Importantly, no assurances are given regarding the finalization of agreements or the successful completion of the deal. Stakeholders are advised that forward-looking statements included may not reflect actual future events.
Read more →COCHAnzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders and Entry into Excise Tax Insurance Agreement Tampa, Florida
Anzu Special Acquisition Corp I announced the adjournment of its Special Meeting of Stockholders to February 28, 2023, without conducting further business. Additionally, the Company has signed an Excise Tax Insurance Agreement to mitigate potential federal excise tax liabilities tied to share redemptions. The adjourned meeting will focus on a proposal to extend the deadline for the Company to complete an initial business combination. The effectiveness of the insurance agreement is contingent on shareholder approval of this proposal.
Read more →COCHAnzu Special Acquisition Corp I Announces Adjournment of Special Meeting of Stockholders Tampa, Florida
Anzu Special Acquisition Corp I announced the adjournment of its special stockholders' meeting originally scheduled for February 9, 2023. The meeting has been rescheduled to February 21, 2023, at 9:30 a.m. Eastern, to allow stockholders to vote on a proposal to extend the deadline for finalizing a business combination. Stockholders have the option to withdraw redemptions until the vote is taken, and further information is available in the company's proxy statement filed with the SEC.
Read more →COCHAnzu Special Acquisition Corp I Announces Forward Purchase Agreements of Up to $120 million and further $120 million right of first offer on potential private placement
Anzu Special Acquisition Corp I Announces Forward Purchase Agreements of Up to $120 million and further $120 million right of first offer on potential private placement TAMPA - Anzu Special Acquisition Corp I (the "Company" or "ANZU"), today announced the signing of forward pu
Read more →COCHAnzu Special Acquisition Corp I Announces the Separate Trading of Its Class A Common Stock and Warrants, Commencing
Special Acquisition Corp I Announces the Separate Trading of Its Class A Common Stock and Warrants, Commencing April 22, 2021 Fla.-(BUSINESS WIRE)-Anzu Special Acquisition Corp I (NASDAQ: ANZUU) (the "Company"), a blank check company sponsored by Anzu SPAC GP I LLC, today annou
Read more →COCHANZU SPECIAL ACQUISITION CORP I
ANZU SPECIAL ACQUISITION CORP I March 4, 2021 Pro Forma Adjustments As adjusted (Unaudited) (Unaudited) Assets Cash $ 4,014,287 $ - $ 4,014,287 Prepaid expenses 1,164,778 - 1,164,778 Total current assets 5,179,065 - 5,179,065
Read more →COCHANZU SPECIAL ACQUISITION CORP I Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
ANZU SPECIAL ACQUISITION CORP I Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of March 4, 2021 F-3 Notes to Financial Statement F-4 Report of Independent Registered Public To the Stockholders and Board of Directors Anzu Special Acquisi
Read more →COCHEnvoy Group Corp/Black Cactus Global Adds Dr. Ravindranath Kancheria To Board
LAS VEGAS, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Envoy Group Corp (OTC Markets:ENVV) (the “Company) is pleased to announce that Dr. Ravindranath Kancheria has joined the Company’s Board of Directors. Dr. Kancheria is a distinguished and internationally recognized Gastrointestinal En
Read more →COCHEnvoyAI launches with 35 algorithms contributed by 14 newly-contracted artificial intelligence development partners
CAMBRIDGE, Mass., Nov. 26, 2017 (GLOBE NEWSWIRE) -- Artificial intelligence platform provider, EnvoyAI (www.envoyai.com) today announced the launch of the EnvoyAI Exchange, a platform described by AuntMinnie as the "Amazon for AI." EnvoyAI launches with 14 signed distribution dea
Read more →COCHEnvoy Group Corp Announces Key Services Agreement
VALENCIA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Envoy Group Corp. (OTC:ENVV) is pleased to announce it has signed a consulting agreement with McCarthy Consultant Services Inc. of Newmarket, Ontario. In operation for over 35 years, McCarthy Consultant Services Inc. (MCSI) has
Read more →COCHEnvoy Agricultural Incorporated Announces Initiation of IPO Process with Wall Street Brokerage Firm
UNIVERSITY, Miss., May 13, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Biopharmaceutical Company Envoy Agricultural Incorporated, specializing in medical marijuana and industrial hemp announced today they will begin their IPO process on Thursday, May 15, 2014 utilizing the services of t
Read more →Competitive Position
How COCH ranks across every disease it competes inCompetitive Position is a premium feature
See how COCH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial